CRDL

Cardiol Therapeutics Inc. [CRDL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CRDL Stock Summary

Top CRDL Correlated Resources

CRDL

Top 10 Correlated ETFs

CRDL

Top 10 Correlated Stocks

CRDL

In the News

CRDL Financial details

Company Rating
-
Market Cap
121.11M
Income
-28.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
-3.2
Forward P/E
-
PEG
0.81
P/S
-
P/B
2.57
P/C
-
P/FCF
-3.26
Quick Ratio
5.08
Current Ratio
5.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
-32.88%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-23.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-65%
ROE
-65%
ROC
-0.87%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.511-2.17
52W High
-
52W Low
-
RSI
48
Rel Volume
0.38
Avg Volume
400.76K
Volume
152.23K
Perf Week
-1.27%
Perf Month
-20.21%
Perf Quarter
-53.02%
Perf Half Y
-36.34%
-
-
-
-
Beta
0.752
-
-
Volatility
0.03%, 0.11%
Prev Close
-0.43%
Price
1.165
Change
6.88%

Something similar

Top by Market Cap
LLY.DE
GOOGL
LLY.SW
EMBASSY.NS
ABEC.DE
Top Correlated ETFs
GLIN
EPI
INDA
SMIN
PIN
Top Correlated Stocks
CRDL.TO
TERN
MEOH
WAB
CRBP
Similar Market Cap
WCBR.L
JLS
SPPX.DE
HGSH
ALGS

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 400.76K
  • Market Capitalization 121.11M
  • Employee 22
  • CEO Mr. David G. Elsley MBA
  • Headquarters Oakville,ON,CA
  • IPO Date 2019-01-15
  • Website https://www.cardiolrx.com

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.